This review found that the development of antibodies against anti-TNF monoclonal antibodies increase risk of treatment discontinuation and hypersensitivity and may decrease clinical response. Combining monoclonal antibodies with other agents reduced the development of antibodies. The evidence was variable in quantity and quality, being more limited for efficacy outcomes, but the main conclusions appear reliable.
Results of the review
Sixty-four studies (13,982 participants) were included in the review: 30 randomised controlled trials (RCTs), 23 prospective and 11 retrospective observational studies. Thirty-seven studies (60%) scored higher than 70% on quality assessment. Where reported, follow-up duration ranged from six to 196 weeks.
Response: A statistically significantly worse response to treatment (measured using EULAR criteria) was observed at six months in seropositive patients with rheumatoid arthritis taking infliximab or adalimumab (OR 0.03, 95% CI 0.01 to 0.21; three studies; I²=49.6%) and at six to 12 months (OR 0.03, 95% CI 0.00 to 0.30; three studies; I²=71.1%). There were no statistically significant differences in response between patients with rheumatoid arthritis, with and without antibodies, when using the American College of Rheumatology 20 response (three studies; I²=62.8%).
Similarly, no statistically significant differences in response to treatment were observed in patients with spondyloarthropathies or inflammatory bowel disease. Seropositive patients with rheumatoid arthritis, psoriasis or inflammatory bowel disease showed a non-statistically significantly higher rate of loss of response to treatment compared to seronegative patients (OR 3.0, 95% CI 0.99 to 9.09; three studies; I²=31.8%).
Safety: Seropositive patients (regardless of condition) showed statistically significant higher rates of hypersensitivity compared to seronegative patients (OR 3.97, 95% CI 2.36 to 6.67; 16 studies; I²=62.5%). Seropositive patients with rheumatoid arthritis showed statistically significantly higher rates of discontinuation of treatment compared to seronegative patients (OR 3.53, 95% CI 1.60 to 7.82; three studies; I²=34.5%). Concomitant treatment with disease modifying antirheumatic drugs (DMARDs) statistically significantly reduced the risk of becoming seropositive (OR 0.32, 95% CI 0.25 to 0.42; 17 studies; I²=0%).
Results from meta-regression and other secondary outcomes were reported in the review. There was evidence of publication bias for response in patients with rheumatoid arthritis but no evidence of bias for other outcomes.
Authors' conclusions
Development of antibodies against anti-TNF monoclonal antibodies decreased clinical response in patients with rheumatoid arthritis and increased risk of discontinuation of treatment and development of hypersensitivity. Combining anti-TNF monoclonal antibodies with DMARDs reduced the development of antibodies and associated risk; therefore, anti-TNF antibodies may not be advisable as monotherapy. Information was limited regarding other biologic agents and other immune-mediated chronic inflammatory diseases.
CRD commentary
The review question was broad but supported by appropriate inclusion criteria. A satisfactory number of sources were searched for relevant data but there was potential for language bias as some language restrictions were applied. Formal assessment of publication bias indicated some evidence of bias but only a small number of studies were assessed. Study quality was assessed but details were not provided. Study selection was performed in duplicate but it was unclear whether this was the case for other stages of the review process so reviewer error and bias could not be ruled out.
A large evidence base was presented but this resulted in significant variability across studies in terms of patients, treatments, outcomes and outcome measures. This was reflected in the high levels of statistical heterogeneity for most outcomes. The authors went some way to explore sources of heterogeneity and only pooled data where they considered the evidence to be sufficient. However, numbers of studies and sample sizes for meta-analyses in outcomes relating to treatment response were generally small.
